Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2007

View Archived Issues

BF-2649 increases wakefulness and cognition in preclinical studies

Catalyst Biosciences signs research collaboration, license agreements with Wyeth

MPC-7869 development discontinued in cancer

NBI-56418 reduces endometriosis symptoms in phase II trial

Fentora studies show onset of pain relief within 10 minutes

Novel recombinant malaria vaccine candidate shows potential in preclinical studies

Vorinostat active in phase II refractory cutaneous T-cell lymphoma trial

Celgene looks back on 2006 and ahead to 2007

Low LDL-C linked to high incidence of Parkinson's disease: statins may lower risk for the disease

Cleviprex phase III safety trials meet objectives

Prochymal receives fast track designation, set to begin phase III for Crohn's disease

FDA grants orphan drug status to Xanafide in AML

Alnylam reveals 2007 goals

Xenoport provides overview of lead programs

Hana looks ahead to 2007 goals

Biolipox selects eoxin inhibitor drug candidate for asthma

Actelion completes cash tender offer for shares of CoTherix

MDX-1401 cleared for phase I study in relapsed or refractory Hodgkin's disease

Anthera cleared to study A-001 in hospitalized patients with sickle cell disease

Novel anticancer drugs revealed in recent patents

Doxil approved in Japan for AIDS-related Kaposi's sarcoma

Korea clears study of VM-106 genetic therapy for chronic granuloma

PRO-513 gives relief from pain, nausea, photophobia and phonophobia in migraine

Erbitux plus FOLFIRI increases PFS in metastatic colorectal cancer

Dll4/Notch blockade leads to nonproductive angiogenesis and tumor hypoxia

New PPAR agonists emerge from Shionogi R&D

Sonazoid contrast agent launched in Japan

TheraSphere approved to treat HCC patients with portal vein thrombosis

Elaprase approved in E.U. for Hunter's syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...